GUIDELINES FOR PULMONARY NODULE MANAGEMENT : RECENT CHANGES AND UPDATES
|
|
|
- Kory French
- 6 years ago
- Views:
Transcription
1 Venice 2017 GUIDELINES FOR PULMONARY NODULE MANAGEMENT : RECENT CHANGES AND UPDATES Heber MacMahon MB, BCh Department of Radiology The University of Chicago
2 Disclosures Consultant for Riverain Medical Minor stockholder in Hologic, Inc. Consultant for GE Healthcare Research Support from Philips Healthcare License and royalty fees from University of Chicago (UC Tech)
3 What is a Pulmonary Nodule?
4 Pulmonary Nodule A rounded opacity, well or poorly defined, measuring up to 3 cm in diameter
5 Nodule Size and Probability of Malignancy Size ELCAP Mayo <3mm 0.1% 2-5mm 1% 4-7mm 0.7% 6-10mm 24% 8-20mm 18.7% 21-30mm 33.3% 21-45mm 80%
6 Diagnostic Features of Nodules Size Morphology Texture Solid, Part solid, Ground glass Calcification Shape Margins Location Growth rate
7 Spectrum of NoduleTexture GGO Part Solid Solid
8 Part-Solid and Non-Solid Nodules in a Screening Program Henschke et al. AJR 2002 ;178: Part-solid: 63% malignant Non-solid: 18% malignant Solid: 7% malignant
9 Persistent Non-Solid nodules 53 NS nodules in 49 pts Persisted or grew for > 1 month 75% were adenoca/ BAC 6% AAH 19% Nodular fibrosis/organizing pna Kim et al. Radiology ,1 p267
10 Atypical Adenomatous Hyperplasia (AAH) Typically GGO <5mm Precursor of adenoca Found in 20% + of lobes resected for lung ca
11 Ground Glass (Non-Solid) Nodule
12 Adenocarcinoma Progression
13 Diagnostic Features of Nodules Size Morphology Texture Attenuation Solid, Part solid, Ground glass Calcium, Fat Shape Margins Location Growth rate
14 Benign Features Laminar Calc. Central Calc. Fat
15 Patterns of Calcification Central Laminated Eccentric Popcorn Diffuse Stippled
16 Calcified Lung Carcinoma Calcium detectable by CT in 10% Usually 2 dystrophic ca++ or engulfed granulomatous ca++ Most calcified carcinomas are 5cm.+ Diffuse, speckled or irregular
17 Diagnostic Features of Nodules Size Morphology Texture Attenuation Shape Margins Solid, Part solid, Ground glass Calcium, Fat Spherical, elliptical, linear Spiculated, lobulated, smooth Location Growth rate
18 Nodule Margins Smooth Lobulated Spiculated
19 Non Solid and Part Solid Nodules Benign Malignant Benign Malignant
20 Malignant (17) versus Benign (12) Non-solid (GGO) Nodules Margins Malignant Benign Rounded 85% 15% Straight 0 100% Li F, Sone S, Abe H, MacMahon H, Doi K: Radiology (3):233, November, 2004.Pages
21 Incidentally detected 5x6mm nodule in a 52 year old never smoker. The most appropriate action would be: , mos CT FU 2. No follow-up 3. PET scan 4. Needle biopsy 5. VATS resection
22 Diagnostic Features of Nodules Size Morphology Texture Calcification Shape Margins Solid, Part solid, Ground glass Central, Laminar, Popcorn Diffuse Spherical, elliptical, linear Spiculated, lobulated, smooth Location Growth rate
23 Small Perifissural Solid Nodules De Hoop B, et al.pulmonary perifissural nodules on CT scans: rapid growth is not a predictor of malignancy. Radiology` 2012;265(2): Myeong I. Ahn MD et al. Perifissural Nodules Seen at CT Screening for Lung Cancer. Radiology: 2010; 254 (3):
24 Diagnostic Features of Nodules Size Morphology Texture Attenuation Shape Margins Location Solid, Part solid, Ground glass Calcium, Fat Spherical, elliptical, linear Spiculated, lobulated, smooth Perifissural, subpleural, upper lobe Growth rate
25 Growth rate of nodules Volume doubling time (VDT): 26% diameter increase = One volume doubling Typical lung ca. VDT = days Range = days
26 Growth rate of Small Cancers (Hasegawa BJR 2000) Parameter Mean VDT (Days) <10mm 536 >20mm 299 Smoker 292 Non-smoker 607 Adenoca 533 Squamous 129 Small cell 97 GGO 813 Mixed Solid
27
28 Fleischner Society Guidelines 2005 Nodule Size (mm) Low-Risk Patient High-Risk Patient 0-4 None 12 mos > mos 6-12, 18-24mos > , 18-24mos 3-6, 9-12, 24mos >8 Follow-up CT at around 3, 9, and 24mo, dynamic contrast-enhanced CT, PET, and/or bx
29 Fleischner Society Guidelines 2005 Nodule Size (mm) Low-Risk Patient High-Risk Patient 0-4 None 12 mos > mos 6-12, 18-24mos > , 18-24mos 3-6, 9-12, 24mos >8 Follow-up CT at around 3, 9, and 24mo, dynamic contrast-enhanced CT, PET, and/or bx Reduced number of scans for benign nodules Reduced expense Reduced radiation exposure
30
31 Fleischner Society Guidelines Solitary Subsolid Nodules (2013): Nodule type Management recommendations Solitary pure GGNs: <5mm >5mm No CT FU required 3 mos, then annual for at least 3 yrs Solitary part-solid nodules: 3 mos FU CT, then annual LDCT if solid part <5mm. If solid part >5mm then consider Bx or surg.
32 Fleischner Society Guidelines Multiple Subsolid Nodules (2013): Nodule type Management recommendations Pure GGNs: <5mm >5mm No CT FU required 3 mos, then annual for at least 3 yrs Dominant Nodules with Part-Solid/Solid Component: 3 mos FU CT, then bx or surgery, especially if solid part <5mm.
33 Incidental Nodules Exclusions: Patients with unexplained fever Patients with known or suspected metastases Patients < 35 years of age Lung Cancer Screening
34 Screening Detected vs Incidental Nodules Screen Detected Nodule Limited age range & high cancer risk Surgical candidate Understand risks and benefits Incidental Nodule Wide age range Comorbid conditions Variable motivation & understanding
35 Screening Detected vs Incidental Nodules Screen Detected Nodule Limited age range & high cancer risk Surgical candidate Understand risks and benefits Negative report > 12 month CT Incidental Nodule Wide age range Comorbid conditions Variable motivation & understanding Negative report > no follow up
36 New Evidence International Early Lung Cancer Action Program (ielcap) National Lung Cancer Screening Trial (NLST) Pan-Canadian Early Detection of Lung Cancer Study (PanCan) & British Columbia Cancer Agency Trial (BCCA) Nederlans-Leuvens Longkanker Screenings Onderzoek (NELSON) UKLS (UK), MILD (Italy), DANTE (Italy), DLCST (Denmark), LUSI (Germany), DEPISCAN (France)
37 Fleischner Guidelines 2017 : Threshold Size Relationship between Nodule Size and Probability That a Nodule Is Lung Cancer. McWilliams A et al. N Engl J Med 2013;369:
38 New Evidence McWilliams A et al. N Engl J Med 2013;369: Factors Odds Ratio Age, per year 1.03 Sex, female vs male 1.82 Family History 1.34 Emphysema 1.34 Nodule Type GGN 0.88 PS 1.46 Solid Reference Nodule Location, upper lobe 1.93 Nodule Count, per extra nodule 0.92
39 Revised Guidelines 2017: Purpose Apply new evidence to determine optimal management strategy Reduce number of unnecessary CT scans
40 Revised Guidelines 2017: Purpose Apply new evidence to determine optimal management strategy Reduce number of unnecessary CT scans Allow greater discretion to radiologists, clinicians and patients in management decisions - Consider morphology - Comorbid conditions - Patient preference
41 Fleischner Guidelines 2017 General recommendations: Contiguous thin section CT technique (1mm) Coronal & sagittal recons Low radiation technique for follow up scans
42 Revised Fleischner Guidelines 2017 General recommendations: Contiguous thin section CT technique (1mm) Coronal & sagittal recons Low radiation technique for follow up scans
43 3mm 1mm Calcified granuloma
44 ? Nodule
45 Axial Coronal Sagittal
46 Revised Fleischner Guidelines 2017 General recommendations: Contiguous thin section CT technique (1mm) Coronal & sagittal recons Low radiation technique for follow up scans
47 Fleischner Society Guidelines 2005 Nodule Size (mm) Low-Risk Patient High-Risk Patient 0-4 None 12 mos > mos 6-12, 18-24mos > , 18-24mos 3-6, 9-12, 24mos >8 Follow-up CT at around 3, 9, and 24mo, dynamic contrast-enhanced CT, PET, and/or bx
48 Fleischner Guidelines 2005 vs 2017 Nodule Size (mm) * Low-Risk Patient High-Risk Patient 0-<4 None 12 mos < 6 None + 12 mos > mos 6-12, 18-24mos > , 18-24mos 3-6, 9-12, 24mos , mos 6-12, 18-24mos >8 Follow-up CT at around 3, 9, and 24mo, dynamic contrast-enhanced CT, PET, and/or bx >8 Consider 3 mos CT, PET/CT or bx *Measure average diameter to nearest millimeter
49 Fleischner Guidelines 2005 vs 2017 Nodule Size (mm) * Low-Risk Patient High-Risk Patient 0-<4 None 12 mos < 6 1 mm change None + 12 mos Less FU > mos 6-12, 18-24mos > , 18-24mos 3-6, 9-12, 24mos 6-8 Only 3 groups 6-12, mos 6-12, 18-24mos >8 Follow-up CT at around 3, 9, and 24mo, dynamic contrast-enhanced CT, PET, and/or bx >8 Consider 3 mos CT, PET/CT or bx *Measure average diameter to nearest millimeter
50 Fleischner Subsolid Guidelines 2013 vs 2017 Nodule Size (mm) * Management recommendations GGN < 5mm No FU < 6mm No FU >5mm 3 mos CT then annual for3 yrs > 6mm 6-12 mos CT then every 2 yrs until 5 yrs PSN < 5mm No FU < 6mm No FU > 5mm 3 mos then annual for 3 yrs > 6mm 3-6 mos CT then annual x 5 yrs
51 Fleischner Subsolid Guidelines 2013 vs 2017 Nodule Size (mm) * Management recommendations GGN < 5mm No FU < 6mm No FU >5mm 3 mos CT then annual for3 yrs > 6mm 6-12 mos CT then every 2 yrs until 5 yrs Same size threshold: < 5mm= <6 PSN when rounding < 5mm No FU < 6mm No FU > 5mm 3 mos then annual for 3 yrs > 6mm 3-6 mos CT then annual x 5 yrs
52 Fleischner Subsolid Guidelines 2013 vs 2017 Multiple Subsolid Nodules Nodule type Pure GGNs: <5mm >5mm <6mm Dominant Nodules with Part-Solid/Solid Component: >6mm Management recommendations No CT FU required 3 mos, then annual for at least 3 yrs 3-6 mos, then +2 and 4 yr CT FU 3 mos FU CT, then bx or surgery, especially if solid part <5mm. 3-6 mos CT, then based on most suspicious nodule
53 Fleischner Subsolid Guidelines 2013 vs 2017 Multiple Subsolid Nodules Nodule type Pure GGNs: <5mm >5mm <6mm Management recommendations No CT FU required 3 mos, then annual for at least 3 yrs 3-6 mos, then +2 and 4 yr CT FU Dominant Nodules with Part-Solid/Solid Component: Multiple Subsolid Nodules 3 mos FU CT, then bx or surgery, especially if solid part <5mm. 3-6 mos CT, then based on most suspicious nodule. If stable, consider 2 and 4 yr CT Optional later first FU, then longer FU
54 Fleischner Subsolid Guidelines 2013 vs 2017 Multiple Subsolid Nodules Nodule type Pure GGNs: <5mm >5mm Dominant Nodules with Part-Solid/Solid Component: Multiple Subsolid Nodules <6mm >6mm Management recommendations No CT FU required 3 mos, then annual for at least 3 yrs 3 mos FU CT, then bx or surgery, especially if solid part <5mm. 3-6 mos CT. If stable, consider 2 and 4 yr CT. 3-6 mos CT. Subsequent management based on the most suspicious nodule.
55 Fleischner Subsolid Guidelines 2013 vs 2017 Multiple Subsolid Nodules Nodule type Pure GGNs: <5mm >5mm Dominant Nodules with Part-Solid/Solid Component: Multiple Subsolid Nodules <6mm >6mm Management recommendations No CT FU required 3 mos, then annual for at least 3 yrs 3 mos FU CT, then bx or surgery, especially if solid part <5mm. 3-6 mos CT. If stable, consider 2 and 4 yr CT. 3-6 mos CT. Subsequent management based on the most suspicious nodule. Same size threshold as before Consider longer FU for some with multiple small subsolids
56 Revised Fleischner Guidelines 2017
57 Fleischner Guidelines 2017 Less routine follow-up for very small nodules More flexibility for follow up timing depending morphology and patient preference Longer follow up for suspicious sub-solid nodules
58
PULMONARY NODULES AND MASSES : DIAGNOSTIC APPROACH AND NEW MANAGEMENT GUIDELINES. https://tinyurl.com/hmpn2018
PULMONARY NODULES AND MASSES : DIAGNOSTIC APPROACH AND NEW MANAGEMENT GUIDELINES Heber MacMahon MB, BCh Department of Radiology The University of Chicago https://tinyurl.com/hmpn2018 Disclosures Consultant
Pulmonary Nodules & Masses
Pulmonary Nodules & Masses A Diagnostic Approach Heber MacMahon The University of Chicago Department of Radiology Disclosure Information Consultant for Riverain Technology Minor equity in Hologic Royalties
LUNG NODULES: MODERN MANAGEMENT STRATEGIES
Department of Radiology LUNG NODULES: MODERN MANAGEMENT STRATEGIES Christian J. Herold M.D. Department of Biomedical Imaging and Image-guided Therapy Medical University of Vienna Vienna, Austria Pulmonary
Evidence based approach to incidentally detected subsolid pulmonary nodule. DM SEMINAR July 27, 2018 Harshith Rao
Evidence based approach to incidentally detected subsolid pulmonary nodule DM SEMINAR July 27, 2018 Harshith Rao Outline Definitions Etiologies Risk evaluation Clinical features Radiology Approach Modifications:
Approach to Pulmonary Nodules
Approach to Pulmonary Nodules Edwin Jackson, Jr., DO Assistant Professor-Clinical Director, James Early Detection Clinic Department of Internal Medicine Division of Pulmonary, Allergy, Critical Care and
Learning Objectives. 1. Identify which patients meet criteria for annual lung cancer screening
Disclosure I, Taylor Rowlett, DO NOT have a financial interest /arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in the context
SCBT-MR 2015 Incidentaloma on Chest CT
SCBT-MR 2015 Incidentaloma on Chest CT Reginald F. Munden MD, DMD, MBA I have no conflicts of interest to report Incidentaloma Pulmonary Nodule Mediastinal Lymph Node Coronary Artery Calcium Incidental
CT Screening for Lung Cancer for High Risk Patients
CT Screening for Lung Cancer for High Risk Patients The recently published National Lung Cancer Screening Trial (NLST) showed that low-dose CT screening for lung cancer reduces mortality in high-risk patients
Lung Cancer screening :
Lung Cancer screening : Pro-Contra SAMO interdisciplinary workshop on chest tumors 27 and 28 january 2017 Prof L.P.Nicod Sevice de pneumologie CHUV-Lausanne -CH Lung Cancer How big is the problem? Epidemiology
OBJECTIVES. Solitary Solid Spiculated Nodule. What would you do next? Case Based Discussion: State of the Art Management of Lung Nodules.
Organ Imaging : September 25 2015 OBJECTIVES Case Based Discussion: State of the Art Management of Lung Nodules Dr. Elsie T. Nguyen Dr. Kazuhiro Yasufuku 1. To review guidelines for follow up and management
Example of lung screening
Justification of the use of CT for individual health assessment of asymptomatic people How to obtain evidence for IHA - Example of lung screening Mathias Prokop, MD PhD Professor of Radiology Radboud University
Lung Cancer Screening: To Screen or Not to Screen?
Lung Cancer Screening: To Screen or Not to Screen? Lorriana Leard, MD Co-Director of UCSF Lung Cancer Screening Program Vice Chief of Clinical Activities UCSF Pulmonary, Critical Care, Allergy & Sleep
Pulmonary Nodules. Michael Morris, MD
Pulmonary Nodules Michael Morris, MD Case 45 year old healthy male Smokes socially Normal physical exam Pre-employment screening remote +PPD screening CXR nodular opacity Case 45 year old healthy male
2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #364: Optimizing Patient Exposure to Ionizing Radiation: Appropriateness: Follow-up CT Imaging for Incidentally Detected Pulmonary Nodules According to Recommended Guidelines National Quality
Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society
This copy is for personal use only. To order printed copies, contact reprints@rsna.org Heber MacMahon, MB, BCh David P. Naidich, MD Jin Mo Goo, MD, PhD Kyung Soo Lee, MD, PhD Ann N. C. Leung, MD John R.
Best Medical Practices: Maximizing Skills, Minimizing Risk Lung Cancer
Best Medical Practices: Maximizing Skills, Minimizing Risk Lung Cancer Optimal Management of Incidental Pulmonary Nodule Ramin Khorasani, MD, MPH Vice Chair, Department of Radiology Director, Center for
Published Pulmonary Nodule Guidelines A Synthesis
Published Pulmonary Nodule Guidelines A Synthesis Dr A Devaraj Royal Brompton Hospital London 4/28/2015 1 And very soon to be published Published ^ Pulmonary Nodule Guidelines A Synthesis Dr A Devaraj
PULMONARY NODULES DETECTED INCIDENTALLY OR BY SCREENING: LOTS OF GUIDELINES BUT WHERE IS THE EVIDENCE?
PULMONARY NODULES DETECTED INCIDENTALLY OR BY SCREENING: LOTS OF GUIDELINES BUT WHERE IS THE EVIDENCE? MICHAEL K. GOULD, MD SENIOR RESEARCH SCIENTIST DIRECTOR FOR HEALTH SCIENCES & IMPLEMENTATION SCIENCE
Low-dose CT Lung Cancer Screening Guidelines for Pulmonary Nodules Management Version 2
Low-dose CT Lung Cancer Screening Guidelines for Pulmonary Nodules Management Version 2 The Committee for Management of CT-screening-detected Pulmonary Nodules 2009-2011 The Japanese Society of CT Screening
I appreciate the courtesy of Kusumoto at NCC for this presentation. What is Early Lung Cancers. Early Lung Cancers. Early Lung Cancers 18/10/55
I appreciate the courtesy of Kusumoto at NCC for this presentation. Dr. What is Early Lung Cancers DEATH Early period in its lifetime Curative period in its lifetime Early Lung Cancers Early Lung Cancers
The small subsolid pulmonary nodules. What radiologists need to know.
The small subsolid pulmonary nodules. What radiologists need to know. Poster No.: C-1250 Congress: ECR 2016 Type: Educational Exhibit Authors: L. Fernandez Rodriguez, A. Martín Díaz, A. Linares Beltrán,
Screening Programs background and clinical implementation. Denise R. Aberle, MD Professor of Radiology and Engineering
Screening Programs background and clinical implementation Denise R. Aberle, MD Professor of Radiology and Engineering disclosures I have no disclosures. I have no conflicts of interest relevant to this
Thoracic CT pattern in lung cancer: correlation of CT and pathologic diagnosis
19 th Congress of APSR PG of Lung Cancer (ESAP): Update of Lung Cancer Thoracic CT pattern in lung cancer: correlation of CT and pathologic diagnosis Kazuma Kishi, M.D. Department of Respiratory Medicine,
The Spectrum of Management of Pulmonary Ground Glass Nodules
The Spectrum of Management of Pulmonary Ground Glass Nodules Stanley S Siegelman CT Society 10/26/2011 No financial disclosures. Noguchi M et al. Cancer 75: 2844-2852, 1995. 236 surgically resected peripheral
DENOMINATOR: All final reports for CT imaging studies with a finding of an incidental pulmonary nodule for patients aged 35 years and older
Quality ID #364: Optimizing Patient Exposure to Ionizing Radiation: Appropriateness: Follow-up CT Imaging for Incidentally Detected Pulmonary Nodules According to Recommended Guidelines National Quality
Rodney C Richie MD FACP FCCP DBIM Texas Life and EMSI
Rodney C Richie MD FACP FCCP DBIM Texas Life and EMSI Pulmonary Nodules Well-circumscribed, radiographic opacities measuring 3 cm in diameter Surrounded by aerated lung Not associated with atelectesis
What to know and what to make of it
Lung Cancer Screening: What to know and what to make of it J. Matthew Reinersman, MD Assistant Professor of Surgery Division of Thoracic and Cardiovascular Surgery Department of Surgery University of Oklahoma
Pulmonary Nodules: When to worry, when to chill. Douglas Arenberg Associate Professor Pulmonary & Critical Care
Pulmonary Nodules: When to worry, when to chill Douglas Arenberg Associate Professor Pulmonary & Critical Care Disclosure MDCH Grant Funds to improve tobacco cessation service in the Michigan Medicine
Screening for Lung Cancer: Are We There Yet?
Screening for Lung Cancer: Are We There Yet? Kavita Garg, MD Professor of Radiology University of CO, Denver Mountain States Cancer Conference Nov 6 th 2010 The Epidemiology of Lung Cancer Tobacco is the
SCBT-MR 2015 LungRADS : Basics
SCBT-MR 2015 LungRADS : Basics Reginald F. Munden MD, DMD, MBA I have no conflicts of interest to report National Lung Cancer Screening Trial 20% lung cancer mortality reduction 6.9% all cause mortality
Lung Cancer Diagnosis for Primary Care
Lung Cancer Diagnosis for Primary Care Daniel Nader, DO, FCCP Cancer Treatment Center of America Case 1 In which of the following situations would the U.S. Preventive Services Task Force (USPSTF) recommend
Guidelines for the Management of Pulmonary Nodules Detected by Low-dose CT Lung Cancer Screening
Guidelines for the Management of Pulmonary Nodules Detected by Low-dose CT Lung Cancer Screening 1. Introduction In January 2005, the Committee for Preparation of Clinical Practice Guidelines for the Management
SCBT-MR 2016 Lung Cancer Screening in Practice: State of the Art
SCBT-MR 2016 Lung Cancer Screening in Practice: State of the Art Reginald F. Munden MD, DMD, MBA I have no conflicts of interest to report National Lung Cancer Screening Trial 20% lung cancer mortality
Xiaohuan Pan 1,2 *, Xinguan Yang 1,2 *, Jingxu Li 1,2, Xiao Dong 1,2, Jianxing He 2,3, Yubao Guan 1,2. Original Article
Original Article Is a 5-mm diameter an appropriate cut-off value for the diagnosis of atypical adenomatous hyperplasia and adenocarcinoma in situ on chest computed tomography and pathological examination?
Christine Argento, MD Interventional Pulmonology Emory University
Christine Argento, MD Interventional Pulmonology Emory University Outline Lung Cancer Statistics Prior Studies for Lung Cancer Screening NLST Studies Following NLST Future Directions Lung Cancer American
LUNG CANCER SCREENING WHAT S THE IMPACT? Nitra Piyavisetpat, MD Department of Radiology Chulalongkorn University
LUNG CANCER SCREENING WHAT S THE IMPACT? Nitra Piyavisetpat, MD Department of Radiology Chulalongkorn University Objective LDCT lung cancer screening (LCS) Potential Benefits & Harms Recommendation of
THE BENEFITS OF BIG DATA
THE BENEFITS OF BIG DATA Disclosures I am a named inventor on a number of patents and patent applications relating to the evaluation of pulmonary nodules on CT scans of the chest which are owned by Cornell
What to Do with Small Lung Nodules Hanh Vu Nghiem, MD William Beaumont Hospital Royal Oak, Michigan
What to Do with Small Lung Nodules Hanh Vu Nghiem, MD William Beaumont Hospital Royal Oak, Michigan Small Lung Nodules What to do with small lung nodules? We biopsy them when requested What are our accuracy
I9 COMPLETION INSTRUCTIONS
The I9 Form is completed for each screening exam at T0, T1, and T2. At T0 (baseline), the I9 documents comparison review of the baseline screen (C2 Form) with any historical images available. At T1 and
Lung Cancer Screening: Evidence and current recommendations
Lung Cancer Screening: Evidence and current recommendations 20 th March 2018 Dr Annette McWilliams Fiona Stanley Hospital University of Western Australia WA Cancer & Palliative Care Network I have no financial
Lung Cancer Screening: A review of the recommendations Friday, November 11th, 2016 from 11:45 to 12:15. Dr. Tunji Fatoye Dr.
Lung Cancer Screening: A review of the recommendations Friday, November 11th, 2016 from 11:45 to 12:15 Dr. Tunji Fatoye Dr. Alan Kaplan Conflict of Interest Disclosure: Speaker Name: Alan Kaplan FINANCIAL
The Maine Lung Cancer Coalition. Working Together to Reduce Lung Cancer in Maine
The Maine Lung Cancer Coalition Working Together to Reduce Lung Cancer in Maine funding Maine Lung Cancer Coalition (MLCC) Webinar Lung Cancer Screening: Following Up On Abnormal Low Dose CT Scans with
C2 COMPLETION INSTRUCTIONS
The C2 Form is completed for each screening exam at T0, T1, and T2. The C2 Form is to be completed by each of the following ACRIN-NLST study staff: the research associate (study coordinator), CT technologist,
Pulmonologist s Perspective
Low-dose CT for lung cancer screening Pulmonologist s Perspective Literature Review Kang-Yun Lee, MD PhD Department of Thoracic Medicine Taipei Medical University- Shuang Ho Hospital Taiwan Local vs. Advanced
With recent advances in diagnostic imaging technologies,
ORIGINAL ARTICLE Management of Ground-Glass Opacity Lesions Detected in Patients with Otherwise Operable Non-small Cell Lung Cancer Hong Kwan Kim, MD,* Yong Soo Choi, MD,* Kwhanmien Kim, MD,* Young Mog
Clinical significance of noncalcified lung nodules in patients with breast cancer
Breast Cancer Res Treat (2016) 159:265 271 DOI 10.1007/s10549-016-3937-2 CLINICAL TRIAL Clinical significance of noncalcified lung nodules in patients with breast cancer Feng Li 1 Samuel G. Armato 1 Maryellen
Lung nodules: size still matters
SERIES RADIOLOGY Lung nodules: size still matters Anna Rita Larici, Alessandra Farchione, Paola Franchi, Mario Ciliberto, Giuseppe Cicchetti, Lucio Calandriello, Annemilia del Ciello and Lorenzo Bonomo
Chest Radiology Interpretation: Findings of Tuberculosis
Chest Radiology Interpretation: Findings of Tuberculosis Get out your laptops, smart phones or other devices pollev.com/chestradiology Case #1 1 Plombage Pneumonia Cancer 2 Reading the TB CXR Be systematic!
Volume and Mass Doubling Times of Persistent Pulmonary Subsolid Nodules Detected in Patients without Known Malignancy 1
Note: This copy is for your personal non-commercial use only. To order presentation-ready copies for distribution to your colleagues or clients, contact us at www.rsna.org/rsnarights. Original Research
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: McWilliams A, Tammemagi MC, Mayo JR, et al. Probability of
Lung Cancer Risk Associated With New Solid Nodules in the National Lung Screening Trial
Cardiopulmonary Imaging Original Research Pinsky et al. Lung Cancer Risk Associated With New Nodules Cardiopulmonary Imaging Original Research Paul F. Pinsky 1 David S. Gierada 2 P. Hrudaya Nath 3 Reginald
Chest imaging III: Nodular pulmonary disease. Ádám Domonkos Tárnoki, MD, PhD Assistant professor Department of Radiology, Semmelweis University 1
Chest imaging III: Nodular pulmonary disease Ádám Domonkos Tárnoki, MD, PhD Assistant professor Department of Radiology, Semmelweis University 1 Pattern 2 Nodular pattern Several round opacity, typically
Detecting Lung Nodules: Challenges and Solutions. Geoffrey D. Rubin, MD, MBA, FACR, FSCBTMR
Detecting Lung Nodules: Challenges and Solutions Geoffrey D. Rubin, MD, MBA, FACR, FSCBTMR Learning Objectives Awareness of lung nodule detection performance Apply best practice for detection of lung nodules
I8 COMPLETION INSTRUCTIONS
The I8 Form is completed for each screening exam at T0, T1, and T2. At T0 (baseline), the I8 Form documents comparison review of the baseline screen (DR Form) with any historical images available. At T1
Clinical Significance of Lung Nodules Reported on Abdominal CT
Cardiopulmonary Imaging Original Research Alpert et al. Significance of Lung Nodules on Abdominal CT Cardiopulmonary Imaging Original Research Jeffrey B. Alpert 1 John P. Fantauzzi Kira Melamud Heather
Malignant solitary pulmonary nodules: assessment of mass growth rate and doubling time at follow-up CT
Original Article Malignant solitary pulmonary nodules: assessment of mass growth rate and doubling time at follow-up CT Jingxu Li*, Tingting Xia*, Xinguan Yang, Xiao Dong, Jiamin Liang, Nanshan Zhong,
REVIEW ARTICLE. Screening for lung cancer with low-dose computed tomography: a review of current status
REVIEW ARTICLE Screening for lung cancer with low-dose computed tomography: a review of current status Henry M. Marshall 1,2, Rayleen V. Bowman 1,2, Ian A. Yang 1,2, Kwun M. Fong 1,2, Christine D. Berg
A Summary from the 2013World Conference on Lung Cancer Sydney, Australia
A Summary from the 2013World Conference on Lung Cancer Sydney, Australia In 2011, the U.S. National Lung Screening Trial (NLST) has demonstrated that low-dose computed tomography (LDCT) screening of high
Abstract Submission Form
Abstract Submission Form All abstracts must be submitted to the AOCR by September 15 th. All information included must be the original work of the author(s) and be in typed form. Incomplete or handwritten
Evaluation of Individuals With Pulmonary Nodules: When Is It Lung Cancer?
CHEST Supplement DIAGNOSIS AND MANAGEMENT OF LUNG CANCER, 3RD ED: ACCP GUIDELINES Evaluation of Individuals With Pulmonary Nodules: When Is It Lung Cancer? Diagnosis and Management of Lung Cancer, 3rd
University of Groningen. Optimization of nodule management in CT lung cancer screening Heuvelmans, Marjolein
University of Groningen Optimization of nodule management in CT lung cancer screening Heuvelmans, Marjolein IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish
Small Pulmonary Nodules: Our Preliminary Experience in Volumetric Analysis of Doubling Times
Small Pulmonary Nodules: Our Preliminary Experience in Volumetric Analysis of Doubling Times Andrea Borghesi, MD Davide Farina, MD Roberto Maroldi, MD Department of Radiology University of Brescia Brescia,
A Comprehensive Cancer Center Designated by the National Cancer Institute
N C I C C C A Comprehensive Cancer Center Designated by the National Cancer Institute Screening and Early Detection of Lung Cancer: Ready for Practice? David S. Ettinger, MD, FACP, FCCP Alex Grass Professor
Mayo Clinic College of Medicine, Rochester, Minnesota, USA
The Oncologist Lung Cancer Commentary: CT Screening for Lung Cancer Caveat Emptor JAMES R. JETT,DAVID E. MIDTHUN Mayo Clinic College of Medicine, Rochester, Minnesota, USA Key Words. CT screening Early
Characteristics of Subsolid Pulmonary Nodules Showing Growth During Follow-up With CT Scanning
CHEST Original Research Characteristics of Subsolid Pulmonary Nodules Showing Growth During Follow-up With CT Scanning Haruhisa Matsuguma, MD ; Kiyoshi Mori, MD ; Rie Nakahara, MD ; Haruko Suzuki, MD ;
The solitary pulmonary nodule: Assessing the success of predicting malignancy
The solitary pulmonary nodule: Assessing the success of predicting malignancy Poster No.: C-0829 Congress: ECR 2010 Type: Scientific Exhibit Topic: Chest Authors: R. W. K. Lindsay, J. Foster, K. McManus;
CT Screening for Lung Cancer: Frequency and Significance of Part-Solid and Nonsolid Nodules
Claudia I. Henschke 1 David F. Yankelevitz 1 Rosna Mirtcheva 1 Georgeann McGuinness 2 Dorothy McCauley 1 0lli S. Miettinen 3 for the ELCAP Group Received June 19, 2001; accepted after revision November
Invasive Pulmonary Adenocarcinomas versus Preinvasive Lesions Appearing as Ground-Glass Nodules: Differentiation by Using CT Features 1
Note: This copy is for your personal non-commercial use only. To order presentation-ready copies for distribution to your colleagues or clients, contact us at www.rsna.org/rsnarights. Sang Min Lee, MD
Professor John K Field PhD, FRCPath University of Liverpool Cancer Research Centre, UK.
Professor John K Field PhD, FRCPath University of Liverpool Cancer Research Centre, UK. J.K.Field@liv.ac.uk 1.8 million new cases in 2012 Bender Nature Outlook 2014 Probability of survival: ALL participants
Outcomes in the NLST. Health system infrastructure needs to implement screening
Outcomes in the NLST Health system infrastructure needs to implement screening Denise R. Aberle, MD Professor of Radiology and Bioengineering David Geffen School of Medicine at UCLA 1 Disclosures I have
Current Approach to Screening for Lung Cancer. James R Jett M.D.
Current Approach to Screening for Lung Cancer James R Jett M.D. Potential Conflicts of Interest I am Chief Medical Officer for Oncimmune Ltd (Biomarkers of Cancer) Co-Editor of Lung Cancer Section of UP-TO-DATE
Projected Outcomes Using Different Nodule Sizes to Define a Positive CT Lung Cancer Screening Examination
DOI:10.1093/jnci/dju284 First published online October 20, 2014 The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
Objectives. Why? Why? Background 11/5/ % incurable disease at presentation Locally advanced disease Metastasis. 14% 5 year survival
Objectives Appraise lung cancer screening trials results Review screening guidelines Lung Cancer Screening: Past, Present and Future Chi Wan Koo, MD Koo.chiwan@mayo.edu Discuss recommendations essential
DISCLOSURE. Lung Cancer Screening: The End of the Beginning. Learning Objectives. Relevant Financial Relationship(s) Off Label Usage
Peninsula Regional Medical Center 12 th Annual Lung Cancer Conference March 9, 2017 Lung Cancer Screening: The End of the Beginning David E. Midthun M.D. Professor of Medicine College of Medicine, Mayo
Lung Cancer Screening: Now What?
Lung Cancer Screening: Now What? Gerold Bepler, M.D., Ph.D. Director, President & CEO Michigan Cancer Consortium, 2013 Annual Meeting, Lansing, MI, 11/20/13 Lung Cancer #1 Cause of Cancer Death for & *
Role of CT imaging to evaluate solitary pulmonary nodule with extrapulmonary neoplasms
Original Research Article Role of CT imaging to evaluate solitary pulmonary nodule with extrapulmonary neoplasms Anand Vachhani 1, Shashvat Modia 1*, Varun Garasia 1, Deepak Bhimani 1, C. Raychaudhuri
Robert J. McKenna M.D. Chief, Thoracic Surgery Cedars Sinai Medical Center
You Smoke, You Get Lung Cancer, You Die: Can Screening Change this Paradigm? Robert J. McKenna M.D. Chief, Thoracic Surgery Cedars Sinai Medical Center AATS Saturday 4/28/2012 Cancer Screening Cancer
How to Analyse Difficult Chest CT
How to Analyse Difficult Chest CT Complex diseases are:- - Large lesion - Unusual or atypical pattern - Multiple discordant findings Diffuse diseases are:- - Numerous findings in both sides 3 basic steps
Stage I synchronous multiple primary non-small cell lung cancer: CT findings and the effect of TNM staging with the 7th and 8th editions on prognosis
Original Article Stage I synchronous multiple primary non-small cell lung cancer: CT findings and the effect of TNM staging with the 7th and 8th editions on prognosis Jingxu Li, Xinguan Yang, Tingting
REVIEW. A practical approach to radiological evaluation of CT lung cancer screening examinations
Cancer Imaging (2013) 13(3), 391 399 DOI: 10.1102/1470-7330.2013.9043 REVIEW A practical approach to radiological evaluation of CT lung cancer screening examinations Xueqian Xie a,b, Marjolein A. Heuvelmans
Lung Cancer Screening: To screen or not to screen?
Lung Cancer Screening: To screen or not to screen? Dan J. Raz, M.D. Co Director, Lung Cancer Screening Program Co Director, LungCancer and Thoracic OncologyProgram Assistant Professor, Thoracic Surgery
Lung Tumor Cases: Common Problems and Helpful Hints
Lung Tumor Cases: Common Problems and Helpful Hints Brandon T. Larsen, MD, PhD Senior Associate Consultant Department of Laboratory Medicine and Pathology Mayo Clinic Arizona Arizona Society of Pathologists
Lung Cancer Screening: Radiologic and Clinical Implications. Katherine R. Birchard, M.D. University of North Carolina at Chapel Hill
Lung Cancer Screening: Radiologic and Clinical Implications Katherine R. Birchard, M.D. University of North Carolina at Chapel Hill Nothing to disclose Objectives In context of NLST: Review Imaging Techniques
Management of Multiple Pure Ground-Glass Opacity Lesions in Patients with Bronchioloalveolar Carcinoma
ORIGINAL ARTICLE Management of Multiple Pure Ground-Glass Opacity Lesions in Patients with Bronchioloalveolar Carcinoma Hong Kwan Kim, MD,* Yong Soo Choi, MD,* Jhingook Kim, MD, PhD,* Young Mog Shim, MD,
American College of Radiology ACR Appropriateness Criteria
American College of Radiology ACR Criteria Radiologic Management of Thoracic Nodules and Masses Variant 1: Middle-aged patient (35 60 years old) with an incidental 1.5-cm lung nodule. The lesion was smooth.
Screening for Lung Cancer: New Guidelines, Old Problems
Screening for Lung Cancer: New Guidelines, Old Problems Robert Schilz DO, PhD Associate Professor of Medicine Interim Chief of the Division of Pulmonary, Critical Care and Sleep Medicine University Hospitals
Lung cancer screening: are we ready now?
Mini-review Lung cancer screening: are we ready now? Gianluca Milanese Giovanni Capretti Nicola Sverzellati Mario Silva Section of Radiology, Department of Surgical Sciences, University Hospital of Parma,
Imaging Decisions Start Here SM
Owing to its high resolution and wide anatomic coverage, dynamic first-pass perfusion 320-detector-row CT outperforms PET/CT for distinguishing benign from malignant lung nodules, researchers from Japan
Imaging in breast cancer. Mammography and Ultrasound Donya Farrokh.MD Radiologist Mashhad University of Medical Since
Imaging in breast cancer Mammography and Ultrasound Donya Farrokh.MD Radiologist Mashhad University of Medical Since A mammogram report is a key component of the breast cancer diagnostic process. A mammogram
The revised lung adenocarcinoma classification an imaging guide
Review Article The revised lung adenocarcinoma classification an imaging guide Natasha Gardiner 1, Sanjay Jogai 2, Adam Wallis 3 1 Specialty Registrar in Clinical Radiology, Wessex Deanery, UK; 2 Consultant
Deppen S, et al. Annals of Thoracic Surgery 2011;92:
Deppen S, et al. Annals of Thoracic Surgery 2011;92:428-33. http://www.nationmaster.com/graph/ mor_his-mortality-histoplasmosis http://www.humirarems.com/brochure.aspx Baddley, John W., et al. Emerging
Recommendations for the Management of Subsolid Pulmonary Nodules Detected at CT: A Statement from the Fleischner Society 1
Note: This copy is for your personal non-commercial use only. To order presentation-ready copies for distribution to your colleagues or clients, contact us at www.rsna.org/rsnarights. Original Research
Comparison of three mathematical prediction models in patients with a solitary pulmonary nodule
Original Article Comparison of three mathematical prediction models in patients with a solitary pulmonary nodule Xuan Zhang*, Hong-Hong Yan, Jun-Tao Lin, Ze-Hua Wu, Jia Liu, Xu-Wei Cao, Xue-Ning Yang From
Subsolid lung nodules, also termed ground-glass nodules
ORIGINAL ARTICLE Long-Term Surveillance of Ground-Glass Nodules Evidence from the MILD Trial Silva Mario, MD,* Sverzellati Nicola, MD, PhD,* Manna Carmelinda, MD,* Negrini Giulio, MD,* Marchianò Alfonso,
UW Radiology Review Course Breast Calcifications. BI-RADS 5 th Edition
UW Radiology Review Course Breast Calcifications Grace Kalish, MD Vantage Radiology BI-RADS 5 th Edition Benign Skin Vascular Large rod like Coarse popcorn Suspicious Amorphous Coarse heterogenous Fine
Adenocarcinoma in pure ground glass nodules: histological evidence of invasion and open debate on optimal management
Editorial Adenocarcinoma in pure ground glass nodules: histological evidence of invasion and open debate on optimal management Gianluca Milanese 1, Nicola Sverzellati 1, Ugo Pastorino 2, Mario Silva 1
Multifocal Lung Cancer
Multifocal Lung Cancer P. De Leyn, MD, PhD Department of Thoracic Surgery University Hospitals Leuven Belgium LEUVEN LUNG CANCER GROUP Department of Thoracic Surgery Department of Pneumology Department
VA PARTNERSHIP Increase ACCESS to LUNG SCREENING
VA PARTNERSHIP Increase ACCESS to LUNG SCREENING Project PI: Drew Moghanaki, MD, MPH Clinical Co-PI: Claudia Henschke, PhD, MD Technical Co-PI: Rick Avila, MS Sponsored by the Bristol-Myers Squibb Foundation
Lung cancer Screening
Lung cancer Screening Family Physicians and CancerControl 2018 Alain Tremblay Division of Respiratory Medicine University of Calgary Disclosures BD Inc - Consultant / Medical Device development Olympus
MANAGEMENT RECOMMENDATIONS
1 MANAGEMENT RECOMMENDATIONS 1. Adrenal masses!!!!!!! page 2 2. Liver Masses!!!!!!! page 3 3. Obstetric US Soft Markers for Aneuploidy!! pages 4-6 4. Ovarian and Adnexal Cysts!!!!! pages 7-10 5. Pancreatic